LRRC32

LRRC32

LRRC32 Overview

Molecule Name
Transforming growth factor beta activator LRRC32
Synonyms
GARP,Garpin,D11S833E
Drug Development Progress
Drugs in Clinical Trials7
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
Leucine Rich Repeat Containing 32,D11S833E,Garpin,Leucine-Rich Repeat-Containing Protein 32,LRRC32,Transforming Growth Factor Beta Activator LRRC32,GARP,Glycoprotein A Repetitions Predominant
Background
Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells. LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells. The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation.

LRRC32 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
LivmoniplimabMGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115Phase 3 ClinicalArgenx Se
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours
Details
Anti-GARP Chimeric Antigen Receptor T Cell Therapy (Ohio State University Comprehensive Cancer Center)Phase 1 ClinicalOhio State University Comprehensive Cancer Center
Glioma
Details
PBA-0111PBA-0111Phase 1 ClinicalPure Biologics SA
Sarcoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
HLX-6018HLX-6018; HLX6018Phase 1 Clinical
Idiopathic Pulmonary Fibrosis
Details
JYB-1907JYB-1907Phase 1 ClinicalJiangxi Jemincare Group Co Ltd
Solid tumours
Details
DS-1055DS-1055; DS-1055aPhase 1 ClinicalDaiichi Sankyo Co Ltd
Neoplasms; Solid tumours
Details
HLX-60HLX-60Phase 1 Clinical
Lymphoma; Solid tumours
Details